Clinical trial · Observational
AutoTransfusion Versus TRAnsfusion in Cancer Surgery
Autotransfusion Versus Transfusion in Cancer Surgery
NCT05452538CI-TRIAL-00074383ATTRACScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Acute bleeding is one of the most frequent intraoperative adverse events and is burdened with a significant morbidity and mortality rate. The only available treatment for severe exsanguination is homologous transfusion, but this is itself complicated by side effects. Nevertheless, systems exist allowing the recovery, treatment and intraoperative reinjection of lost blood, thus limiting transfusions.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Surgery | — | UNRESOLVED | — |
| Hemorrhage | — | UNRESOLVED | — |
| Transfusion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transfusion | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- cancer surgery
- description
- all adult patients operated at the Léon Bérard Centre for cancer surgery (excluding endoscopy, interventional radiology, brachytherapy, vascular access)
- interventionNames
- Device: Transfusion
Primary outcomes (1)
- measure
- number of annual uses of the intraoperative blood recovery system
- timeFrame
- Up to 1 year
- description
- number of annual uses (at the Centre Léon Bérard in 2021) of the intraoperative blood recovery system in the indications validated by the French High Authority for Health
Secondary outcomes (1)
- measure
- annual cost for the Centre Léon Bérard of the transfusion strategy.
- timeFrame
- Up to 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Surgery at the Centre Léon Bérard in 2021 * transfusion from the day of surgery to the 10th postoperative day Exclusion Criteria: * Digestive endoscopy, interventional radiology, brachytherapy * Vascular access only * Patient refusal
References
Publications (4)
- BACKGROUNDKlein AA, Bailey CR, Charlton AJ, Evans E, Guckian-Fisher M, McCrossan R, Nimmo AF, Payne S, Shreeve K, Smith J, Torella F. Association of Anaesthetists guidelines: cell salvage for peri-operative blood conservation 2018. Anaesthesia. 2018 Sep;73(9):1141-1150. doi: 10.1111/anae.14331. Epub 2018 Jul 10. PMID 29989144
- BACKGROUNDWaters JH, Yazer M, Chen YF, Kloke J. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion. 2012 Oct;52(10):2167-73. doi: 10.1111/j.1537-2995.2011.03555.x. Epub 2012 Feb 10. PMID 22321196
- BACKGROUNDUbee SS, Manikandan R, Gudimetla AR, Singh G. Cost benefits of intraoperative cell salvage in radical cystectomy. Indian J Urol. 2010 Apr;26(2):196-9. doi: 10.4103/0970-1591.65386. PMID 20877596
- BACKGROUNDAraujo RL, Pantanali CA, Haddad L, Rocha Filho JA, D'Albuquerque LA, Andraus W. Does autologous blood transfusion during liver transplantation for hepatocellular carcinoma increase risk of recurrence? World J Gastrointest Surg. 2016 Feb 27;8(2):161-8. doi: 10.4240/wjgs.v8.i2.161. PMID 26981190